Kufs Disease, the Major Adult Form of Neuronal Ceroid Lipofuscinosis, Caused by Mutations in CLN6

Epilepsy Research Center, Department of Medicine, University of Melbourne, Austin Health, Heidelberg, Victoria 3084, Australia.
The American Journal of Human Genetics (Impact Factor: 10.99). 05/2011; 88(5):566-73. DOI: 10.1016/j.ajhg.2011.04.004
Source: PubMed

ABSTRACT The molecular basis of Kufs disease is unknown, whereas a series of genes accounting for most of the childhood-onset forms of neuronal ceroid lipofuscinosis (NCL) have been identified. Diagnosis of Kufs disease is difficult because the characteristic lipopigment is largely confined to neurons and can require a brain biopsy or autopsy for final diagnosis. We mapped four families with Kufs disease for whom there was good evidence of autosomal-recessive inheritance and found two peaks on chromosome 15. Three of the families were affected by Kufs type A disease and presented with progressive myoclonus epilepsy, and one was affected by type B (presenting with dementia and motor system dysfunction). Sequencing of a candidate gene in one peak shared by all four families identified no mutations, but sequencing of CLN6, found in the second peak and shared by only the three families affected by Kufs type A disease, revealed pathogenic mutations in all three families. We subsequently sequenced CLN6 in eight other families, three of which were affected by recessive Kufs type A disease. Mutations in both CLN6 alleles were found in the three type A cases and in one family affected by unclassified Kufs disease. Mutations in CLN6 are the major cause of recessive Kufs type A disease. The phenotypic differences between variant late-infantile NCL, previously found to be caused by CLN6, and Kufs type A disease are striking; there is a much later age at onset and lack of visual involvement in the latter. Sequencing of CLN6 will provide a simple diagnostic strategy in this disorder, in which definitive identification usually requires invasive biopsy.

Download full-text


Available from: Stefano Meletti, Jun 20, 2015
1 Follower
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Tripeptidyl-peptidase 1 (TPP1) null or residual activity occurs in neuronal ceroid lipofuscinosis (NCL) with underlying TPP1/CLN2 mutations. A survey of 25 South American CLN2 affected individuals enabled the differentiation of two phenotypes: classical late-infantile and variant juvenile, each in approximately 50% of patients, with residual TPP1 activity occurring in approximately 32%. Each individual was assigned to one of three subgroups: (I) n=11, null TPP1 activity in leukocytes; (II) n=8, residual TPP1 activity of 0.60-15.85nmol/h/mg (nr 110-476); (III) n=6, activity not measured in leukocytes. Curvilinear bodies (CB) appeared in almost all studied CLN2 subjects; the only exceptions occurred in cases of subgroup II: two individuals had combined CBs/fingerprints (FPs), and one case had pure FPs. There were 15 mutations (4 first published in this paper, 3 previously observed in South America by our group, and 8 previously observed by others). In subgroup I, mutations were either missense or nonsense; in subgroups II and III, mutations prevailed at the non-conserved intronic site, c.887-10A>G (intron 7), and to a lesser extent at c.89+5G>C (intron 2), in heterozygous combinations. Grouping phenotypically and genetically known individuals on the basis of TPP1 activity supported the concept that residual enzyme activity underlies a protracted disease course. The prevalence of intronic mutations at non-conserved sites in subgroup II individuals indicates that some alternative splicing might allow some residual TPP1 activity.
    Gene 12/2012; 516(1). DOI:10.1016/j.gene.2012.12.058 · 2.08 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The progressive myoclonus epilepsies (PME) are neurodegenerative diseases with prominent myoclonus and epilepsy. They are mostly, though not exclusively, diseases of children, and are mostly, though not exclusively, fatal. This review includes only those PME where more than one family has been described. The largest group of PME is the neuronal ceroid lipofuscinoses (NCL). The genetics of the NCL is representative of the larger group. Most, but not all, are monogenic, autosomal recessive inherited diseases, and most diseases genes, but not all, encode lysosomal proteins. One of the major questions in PME is "why PME"? That is, why do these neurodegenerative diseases result in so much epileptogenesis? Perhaps, the answers to "why epilepsy?" underlying this entire volume on genetics of epilepsy, will be aided by this group of the severest of epilepsies, where most, probably almost all, genes are already known. As therapies go, while not much is available yet, most of the PME start from a point of initial normalcy, and have a period of minimal symptoms close to onset, and most are relatively simple metabolic diseases. Hence, among the intractable epilepsies, hope for treatments and cures is likely the strongest in this group of diseases.
    Progress in brain research 01/2014; 213C:113-122. DOI:10.1016/B978-0-444-63326-2.00006-5 · 5.10 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: To define the clinical spectrum and etiology of progressive myoclonic epilepsies (PMEs) in Italy using a database developed by the Genetics Commission of the Italian League against Epilepsy. We collected clinical and laboratory data from patients referred to 25 Italian epilepsy centers regardless of whether a positive causative factor was identified. PMEs of undetermined origins were grouped using 2-step cluster analysis. We collected clinical data from 204 patients, including 77 with a diagnosis of Unverricht-Lundborg disease and 37 with a diagnosis of Lafora body disease; 31 patients had PMEs due to rarer genetic causes, mainly neuronal ceroid lipofuscinoses. Two more patients had celiac disease. Despite extensive investigation, we found no definitive etiology for 57 patients. Cluster analysis indicated that these patients could be grouped into 2 clusters defined by age at disease onset, age at myoclonus onset, previous psychomotor delay, seizure characteristics, photosensitivity, associated signs other than those included in the cardinal definition of PME, and pathologic MRI findings. Information concerning the distribution of different genetic causes of PMEs may provide a framework for an updated diagnostic workup. Phenotypes of the patients with PME of undetermined cause varied widely. The presence of separate clusters suggests that novel forms of PME are yet to be clinically and genetically characterized.
    Neurology 02/2014; 82(5):405-11. DOI:10.1212/WNL.0000000000000077 · 8.30 Impact Factor